Argenx News and Activities

Presence

Argenx is a biotechnology company that develops and sells antibody-based medicines for autoimmune diseases and cancer. Its products and research services support hospitals, specialists, and patients who need new treatment options.

Argenx products and services overview:

Autoimmune therapies
Cancer therapies
Antibody medicines
Drug development

Revenue: ~$2 billion

Employees: 1,700

Headquarters: Ghent, Belgium

Argenx is one of the...

Argenx is a company listed under the stock ticker ARGX (BE).

Argenx has a direct presence in 2 countries.

Executives

View the org chart displaying its 33 main executives

Most searched biographies at Argenx

Popular executive movements at Argenx

Peter Verhaeghe, Non-executive director and Chairman of the Board, will retire on Mar. 6, 2026 (posted on January 5 2026).
Tim Van Hauwermeiren who is Chief Executive Officer and Director, will be promoted to Non-Executive Director and Chairman of The Board of Directors on Mar. 6, 2026 (posted on January 5 2026).
Karen Massey who is Chief Operating Officer, will be promoted to Chief Executive Officer on Mar. 6, 2026 (posted on January 5 2026).

Create your alert
to follow the executive moves at Argenx.